A literature review of the newest muscle relaxant: ORG 9426.
This article reviews the literature on the newest muscle relaxant, ORG 9426. It has completed clinical trials in the United States and is awaiting final approval from the Food and Drug Administration. Research is presented in regards to the potency, chemical structure, mechanism of action, neuromuscular effects, cardiovascular effects, and possible drug interactions of ORG 9426. Its effect on renal and liver failure patients and on the pediatric and elderly population is also documented. The pharmacodynamics and pharmacokinetics are compared with other neuromuscular blocking agents based on current reports. ORG 9426 is a promising, effective, and rapidly acting muscle relaxant that offers several advantages over other neuromuscular blocking agents presently available.
Combs
J M
JM
Combs
G N
GN
D000328:Adult; D000367:Age Factors; D000368:Aged; D000732:Androstanols / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004347:Drug Interactions; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008875:Middle Aged; D000077123:Rocuronium
D000732:Androstanols; D000077123:Rocuronium